Urolithin A, Mitophagy and Longevity: PINK1/Parkin Pathway Activation, the ATLAS and TIMELINE Trials, and the Diabetic Peripheral Neuropathy Schwann Cell Mitochondrial Quality Control Connection

Every mitochondrion has a lifespan. As mitochondria age within the cell, they accumulate oxidative damage to their inner membrane proteins and mtDNA, progressively lose the electrochemical proton gradient that drives ATP synthesis, and increasingly leak electrons from the respiratory chain as reactive oxygen species rather than channeling them productively through Complex IV. Left unchecked, damaged mitochondria become cellular liabilities rather than assets — triggering NLRP3 inflammasome activation through cytosolic mtDNA leakage, initiating apoptotic cascades via cytochrome c release, and chronically elevating oxidative stress through sustained ROS emission. The cellular mechanism evolved to prevent this mitochondrial quality crisis is mitophagy: a form of selective autophagy in which the PINK1/Parkin serine kinase and E3 ubiquitin ligase partnership identifies damaged mitochondria by their collapsed membrane potential, coats them in ubiquitin chains, and delivers them to lysosomes for controlled degradation and component recycling.

Urolithin A (UA) has emerged as one of the most pharmacologically interesting naturally occurring mitophagy inducers identified to date. Unlike resveratrol — which induces broad autophagy with limited mitophagy specificity — UA operates through at least three mechanistically converging actions centered on the PINK1/Parkin pathway: covalent inhibition of USP30, the deubiquitinase that normally attenuates mitophagy by stripping ubiquitin from damaged mitochondrial outer membrane proteins; AMPK activation with downstream mTORC1 suppression and ULK1 activation; and NAD+-SIRT1-PGC-1α-driven mitochondrial biogenesis that couples mitophagy clearance with organelle renewal. UA is produced when gut microbiota metabolize dietary ellagitannins from pomegranates, walnuts, and raspberries — but profound inter-individual variation in microbiome composition means that approximately 20% of people produce no UA regardless of diet, establishing a strong rationale for direct supplementation.

The human clinical evidence for UA is anchored by two Amazentis-conducted landmark trials. The ATLAS trial (Andreux et al. 2019, Nature Metabolism) enrolled 60 healthy elderly individuals and demonstrated for the first time in humans that oral UA supplementation at 500–2000 mg/day upregulates mitochondrial biogenesis gene programs (TFAM, SDHA, CYTB) in skeletal muscle biopsies and modulates autophagy biomarkers in peripheral blood mononuclear cells — establishing proof of pharmacodynamic activity in human tissue. The TIMELINE trial (Rinsch et al. 2022, Nature Aging) then conducted a rigorous 12-week randomized controlled trial in 88 sedentary older adults, demonstrating that UA at 500 and 1000 mg/day produced dose-dependent reductions in plasma acylcarnitines (C10, C12, C14 — direct markers of incomplete mitochondrial β-oxidation indicating dysfunctional mitochondria) and significant upregulation of OXPHOS gene expression in skeletal muscle. These findings established UA as the first nutritional compound with RCT-level evidence for mitochondrial quality improvement in human aging.

The intersection of UA science with diabetic peripheral neuropathy (DPN) is mechanistically precise. Schwann cells — the myelinating glial cells that ensheath peripheral axons and maintain nerve conduction velocity through myelin maintenance and axonal metabolic support — sustain exceptionally high mitochondrial metabolic demands. In the hyperglycemic and methylglyoxal-rich microenvironment of diabetes, PINK1 protein levels in Schwann cells are directly suppressed by AGE-modification of PINK1’s kinase domain, USP30 expression is paradoxically upregulated by NF-κB-driven inflammatory transcription, and PARKIN undergoes nitrosylation at its RING domains that impairs its E3 ligase activity. The convergent result is a profound mitophagy failure: dysfunctional mitochondria accumulate in Schwann cells, ATP production falls, fatty acid synthesis for myelin membrane production drops, and progressive demyelination ensues — independent of, but compounding, the glucose-mediated axonal sorbitol accumulation and AGE-RAGE signaling that are the traditional focus of DPN management.

What Is Urolithin A? Gut Microbiota Metabolism of Ellagitannins and the Metabotype Problem

Urolithin A is not present in any food in bioactive form. It is produced exclusively by specific gut bacteria through a multi-step metabolic cascade beginning with the hydrolysis of dietary ellagitannins — complex polyphenol esters abundant in pomegranates (as punicalagins and punicalins, constituting up to 4 g per 240 mL of commercial pomegranate juice), walnuts (pedunculagin, tellimagrandin I and II, comprising up to 10% of total polyphenol content), raspberries and blackberries (lambertianin C, sanguiin H-6), and to lesser degrees in strawberries, muscadine grapes, and oak barrel-aged wines. Hydrolysis liberates ellagic acid, which is then sequentially metabolized by Gordonibacter urolithinfaciens (formerly Gordonibacter pamelaeae), Ellagibacter isourolithinifaciens, and Akkermansia muciniphila through a stepwise dehydroxylation and lactonization sequence producing the urolithin family: urolithin M7 → urolithin D → urolithin C → urolithin B → urolithin A, with urolithin A representing the terminal, most bioactive metabolite of this pathway. Notably, some gut bacteria can also produce isourolithin A (IsoUro-A), a regioisomer with overlapping but distinct mitophagy-activating properties currently under parallel investigation.

The clinical and scientific importance of gut microbiome composition for UA production cannot be overstated. Population microbiome studies — most comprehensively the European multi-center study by Selma et al. (2014) and the Amazentis metabotype characterization studies — have identified three metabotypes with distinct urolithin production capacities. Metabotype A individuals (approximately 40% of Western populations) harbor robust communities of all three key UA-producing genera and convert dietary ellagitannins efficiently to UA, achieving plasma UA concentrations of 0.5–3 μM after dietary ellagitannin consumption. Metabotype B individuals (approximately 40%) produce a mixture of urolithins B, isourolithin A, and sub-optimal quantities of UA, with lower mitophagy-activating potency. Metabotype 0 individuals (approximately 20%) produce essentially no urolithins due to the absence or insufficiency of the required bacterial strains — a gut microbiome phenotype associated with reduced Firmicutes diversity, high-fat/low-fiber dietary patterns, antibiotic history, and advanced age. The Metabotype 0 prevalence increases with aging and obesity — the very populations most in need of mitophagy enhancement — creating a profound therapeutic paradox in dietary approaches. Direct UA supplementation completely circumvents metabotype variation by bypassing gut bacteria entirely.

Following intestinal absorption, UA undergoes Phase II conjugation in the enterocytes and hepatocytes, circulating primarily as UA-3-glucuronide (UA-3-GlcUA) and UA-3-sulfate (UA-3-SO4), with free UA representing a minor fraction of total plasma UA. The pharmacokinetics of supplemental UA have been characterized across multiple dose levels in the ATLAS safety/pharmacology study: UA 250, 500, 1000, and 2000 mg produced mean total plasma UA Cmax of approximately 2.5, 5.2, 9.8, and 15.3 μM respectively, with Tmax at 4–6 hours post-dose and a biphasic elimination half-life of approximately 6–12 hours (initial) and 24–36 hours (terminal). The active form in tissues is believed to be the unconjugated free UA released by tissue β-glucuronidases and sulfatases in target organs including skeletal muscle, liver, kidney, and peripheral nervous tissue — consistent with UA’s documented pharmacodynamic activity in skeletal muscle biopsies obtained in the ATLAS trial despite low free UA plasma fractions. Crucially, unconjugated UA achieves micromolar concentrations in peripheral nerve tissue in rodent pharmacokinetic studies, making the Schwann cell mitochondrial quality targets pharmacologically accessible.

The PINK1/Parkin Mitophagy Pathway: Molecular Architecture of Mitochondrial Quality Control

The PINK1/Parkin pathway constitutes the cell’s primary mitochondrial surveillance and quality control system — a molecular logic gate that continuously monitors mitochondrial membrane integrity and triggers selective degradation of organelles that fail to maintain their electrochemical potential. The architecture of this pathway is built on a simple but elegant principle: PINK1 (PTEN-induced kinase 1, encoded by the PARK6 gene) is constitutively imported into healthy mitochondria via the TOM/TIM23 translocase machinery and immediately cleaved and degraded — maintaining PINK1 at near-undetectable steady-state levels on healthy, polarized mitochondria. When mitochondrial membrane potential (ΔΨm) collapses due to irreversible damage — whether from oxidative modification of electron transport chain complexes, mtDNA mutation accumulation, lipid peroxidation of the inner membrane, or protein aggregate burden — the TIM23 import complex is inactivated, PINK1 import is arrested, and full-length PINK1 accumulates on the outer mitochondrial membrane (OMM), where it dimerizes and activates its kinase activity through trans-autophosphorylation at Thr257 and Ser228.

Activated PINK1 executes a two-substrate phosphorylation program that initiates the mitophagy cascade with extraordinary specificity. The first substrate is ubiquitin itself: PINK1 phosphorylates ubiquitin at serine 65 (pUb-S65), and this phosphoubiquitin mark serves as the high-affinity recognition signal that recruits cytosolic Parkin (an RBR-class E3 ubiquitin ligase) from its autoinhibited conformation in the cytoplasm to the OMM surface. The second substrate is Parkin itself: PINK1 phosphorylates the ubiquitin-like (Ubl) domain of Parkin at Ser65, releasing the intramolecular contacts that keep Parkin’s RING0-RING1 autoinhibitory interface closed, allowing Parkin’s catalytic cysteine (Cys431) to engage ubiquitin-loaded E2 conjugating enzymes (UBE2L3, UBE2D). Activated Parkin then ubiquitinates multiple OMM substrate proteins: MFN1 and MFN2 (blocking mitochondrial fusion to prevent dilution of damage markers into the healthy network), VDAC1/2 (creating a physical scaffold for autophagy receptor binding), TOM20 (blocking further mitochondrial import), and MIRO1/2 (arresting mitochondrial movement along microtubules to prevent axonal trafficking of damaged organelles). Importantly, Parkin-generated K48 and K63 polyubiquitin chains are also substrates for PINK1 phosphorylation, creating a feedforward amplification loop that exponentially increases the ubiquitin signal on the damaged OMM.

The phosphoubiquitin-decorated OMM surface then recruits a quartet of autophagy cargo receptors — NDP52 (nuclear dot protein 52/CALCOCO2), OPTN (optineurin), TAX1BP1, and p62/SQSTM1 — each of which bridges the mitochondrial ubiquitin signal to the autophagy machinery via simultaneous engagement of phosphoubiquitin chains through their UBA or UBAN domains and LC3/GABARAP proteins on the expanding phagophore membrane through their LIR motifs. Recent structural work has established a hierarchical receptor architecture: NDP52 and OPTN are the primary initiating receptors (recruited early, responsible for triggering phagophore nucleation at the OMM) while p62/SQSTM1 and TAX1BP1 function as amplifiers (recruited later, stabilizing the growing phagophore-mitochondrion interaction). The phagophore membrane, generated from ER omegasomes and recycling endosomes, expands around the ubiquitin-decorated mitochondrion and eventually seals to form the mitophagosome — a 0.5–2 μm double-membrane vesicle. Mitophagosome fusion with lysosomes is mediated by RAB7-PLEKHM1 tethering factors and SNARE-mediated membrane fusion, delivering the mitochondrial cargo to the acidic lysosomal lumen for proteolytic, lipolytic, and nucleolytic degradation. Salvaged amino acids, fatty acids, and nucleotides are exported via lysosomal transporters (SLC38A9, NPC1, ABCB9) to support new mitochondrial biogenesis.

This elegantly designed clearance system is actively counterbalanced by the deubiquitinase USP30, which is anchored to the OMM via a single N-terminal transmembrane helix with its catalytic domain facing the cytoplasm. USP30 constitutively removes ubiquitin from TOM20, TOMM20, MFN1/2, and VDAC1/2 — opposing Parkin’s ubiquitination at each of these substrates and raising the effective threshold of ΔΨm collapse required to trigger mitophagy. This makes USP30 a quantitative gating mechanism for mitophagy sensitivity: high USP30 activity (observed in aging, in response to NF-κB-driven inflammatory transcription, and in various disease states including Parkinson’s disease and diabetic neuropathy) raises the mitophagy threshold, allowing increasingly damaged mitochondria to escape clearance. Conversely, USP30 genetic knockdown or pharmacological inhibition lowers the threshold, enabling mitophagy of mitochondria that are moderately damaged but not severely enough to trigger pathway activation in the presence of normal USP30 activity. The discovery that UA covalently and selectively inhibits USP30 provided the molecular rationale for its potent mitophagy-enhancing activity.

How Urolithin A Activates Mitophagy: USP30 Inhibition, AMPK Cross-talk, and PGC-1α Biogenesis Coupling

The mechanistic basis for UA’s mitophagy-enhancing activity has been elucidated across multiple independent laboratories since the landmark Ryu et al. (2016) Nature Medicine publication first identified UA as a mitophagy inducer in C. elegans and mouse skeletal muscle. The most directly characterized mechanism is USP30 inhibition: Schäfer et al. (2021, Nature Communications) demonstrated through competitive activity-based protein profiling (ABPP) and mass spectrometry that UA forms a covalent adduct with the active-site cysteine (Cys77) of USP30 via Michael addition, exploiting the electrophilic character of UA’s α,β-unsaturated lactone moiety. This selective USP30 inhibition produces measurable downstream effects in CCCP-treated HeLa cells: a 3.2-fold increase in TOM20 ubiquitination (USP30’s primary substrate at the OMM), a 2.8-fold increase in LC3-II abundance relative to p62 (indicating accelerated mitophagy flux through increased autophagosome formation with maintained lysosomal clearance), and a 45% reduction in mitochondria-associated ubiquitin turnover time — all consistent with lower USP30-mediated deubiquitination allowing Parkin-tagged ubiquitin to persist and recruit downstream autophagy receptors more efficiently. The selectivity of UA for USP30 over other ubiquitin-specific proteases (tested against USP7, USP14, USP18, USP30) was confirmed by differential ABPP profiling, with USP30 showing the highest UA-cysteine occupancy at pharmacologically relevant concentrations.

Parallel to USP30 inhibition, UA activates AMPK (AMP-activated protein kinase) through a mechanism that involves mitochondrial inner membrane Complex I-driven changes in AMP:ATP ratio — UA’s initial mitophagy induction creates a transient bioenergetic shift as dysfunctional mitochondria are cleared before new ones are generated, elevating AMP:ATP and triggering AMPK Thr172 phosphorylation by LKB1. AMPK activation then engages multiple convergent pro-mitophagy signals: phosphorylation of Raptor at Ser722/Ser792 (inhibiting mTORC1 assembly) and of TSC2 at Thr1227/Ser1345 (promoting TSC1/2-mediated Rheb-GAP activity) together suppress mTORC1-mediated inhibitory phosphorylation of ULK1 at Ser757; simultaneous direct AMPK phosphorylation of ULK1 at Ser555 activates ULK1’s autophagy-initiating kinase cascade; and AMPK-driven phosphorylation of Beclin-1 at Ser93/Ser96 promotes autophagy nucleation complex (Beclin-1/VPS34/ATG14L) assembly. The net effect is a broad permissive environment for mitophagy in which both the general autophagy machinery (phagophore nucleation, LC3 lipidation) and the mitophagy-specific pathway (USP30 inhibition, PINK1/Parkin) are simultaneously enhanced — creating a synergistic amplification that exceeds what either mechanism alone would achieve.

The third major mechanism by which UA supports mitochondrial quality is through NAD+-SIRT1-PGC-1α driven mitochondrial biogenesis — ensuring that the mitophagy-induced clearance of damaged organelles is coupled with the synthesis of new, functional replacements. UA’s mitophagy induction reduces the chronic burden of ROS-emitting damaged mitochondria, decreasing oxidative DNA damage and the associated PARP1 hyperactivation that consumes NAD+ as a substrate for poly(ADP-ribose) synthesis. The resulting increase in cellular NAD+ availability enhances SIRT1 deacetylase activity (SIRT1 is obligately dependent on NAD+ as a cofactor), and SIRT1 deacetylates and activates PGC-1α at Lys183 and Lys468 — releasing PGC-1α from the acetyl-repressed state that predominates in aged or metabolically stressed cells. Activated PGC-1α coactivates NRF1 and TFAM, driving transcription of nuclear-encoded OXPHOS subunit genes (CYTB, SDHA, NDUFB6, COX4I1) and mtDNA replication respectively. Independent of SIRT1, AMPK also directly phosphorylates PGC-1α at Thr177 and Ser538, providing a parallel activation axis. The combined result is a mitochondrial quality renewal cycle — clearing damaged mitochondria while simultaneously synthesizing their functional replacements — that mechanistically parallels the mitochondrial remodeling achieved by caloric restriction and aerobic exercise but through distinct molecular entry points.

Ryu 2016 (Nature Medicine): Urolithin A Extends Lifespan 45% in C. elegans and Restores Muscle Function in Aged Mice

The foundational longevity science for urolithin A was published in 2016 when Dongryeol Ryu, Johan Auwerx, and colleagues at the École Polytechnique Fédérale de Lausanne (EPFL) reported in Nature Medicine that UA extended lifespan in C. elegans by approximately 45% and rescued age-associated muscle function decline in aged mice — establishing UA as the first gut microbiota-derived metabolite with documented longevity effects in multiple model organisms. The C. elegans experiments demonstrated that UA at 50 μM extended mean lifespan by 45.4% and maximum lifespan by 40.7% relative to vehicle-treated controls, with the lifespan extension fully abrogated in dct-1 (BNIP3L ortholog), pink-1, and pdr-1 (Parkin ortholog) loss-of-function mutants — genetically confirming that the longevity benefit was specifically dependent on the mitophagy pathway rather than broader autophagy or hormetic stress mechanisms. Time-lapse fluorescence microscopy of mitochondria-targeted GFP reporters in C. elegans muscle cells showed that UA treatment reduced the accumulation of fragmented, depolarized mitochondria in aged worms, consistent with enhanced clearance of dysfunctional organelles.

The mouse experiments in Ryu et al. 2016 employed two complementary models. In the first, aged mice (21–24 months) received UA at 50 mg/kg/day by oral gavage for 5 weeks. UA-treated aged mice showed significantly improved grip strength, rotarod performance, and endurance on exhaustive treadmill testing compared to aged vehicle controls, with grip strength values approaching those of young (4-month) control mice — a striking phenotypic rescue that placed UA alongside caloric restriction and rapamycin in the small category of interventions that meaningfully reverse age-associated muscle function in mammals. Electron microscopy of gastrocnemius muscle biopsies showed that UA treatment reduced the percentage of mitochondria classified as structurally abnormal (disrupted cristae, swollen matrix, outer membrane rupture) from 44% in aged controls to 18% in UA-treated mice — a near-complete normalization toward the 12% found in young controls. In the second model, UA restored impaired swimming endurance in high-fat-diet-fed mice, suggesting relevance to the obesity and metabolic disease context in which mitochondrial quality control is most severely compromised. Transcriptomic analysis of skeletal muscle from UA-treated mice showed significant upregulation of 149 mitochondrial genes and downregulation of 62 genes associated with inflammation and apoptosis — a gene expression fingerprint distinct from that produced by resveratrol or rapamycin, suggesting unique mechanistic action.

The ATLAS Trial (Andreux et al. 2019, Nature Metabolism): First Human Proof of Urolithin A Mitophagy Induction

The Amazentis ATLAS trial (A Trial with Urolithin A to test Safety) represented a critical translational milestone: the first demonstration that orally administered UA induces mitophagy-relevant molecular changes in human tissue. Published by Andreux, Rinsch, and colleagues in Nature Metabolism in 2019, the ATLAS trial enrolled 60 healthy adults aged 65–90 years in a dose-escalation safety and pharmacodynamic study, administering UA as a novel food supplement (Mitopure, a standardized UA formulation) at 250 mg/day, 500 mg/day, 1000 mg/day, or 2000 mg/day for 4 weeks, with a placebo comparator arm. The primary endpoints were safety and tolerability; secondary endpoints included pharmacokinetics, skeletal muscle gene expression (from vastus lateralis biopsies), and blood biomarkers of mitochondrial biogenesis and autophagy.

The ATLAS safety data were uniformly reassuring: UA was well tolerated at all dose levels with no dose-limiting adverse events, no changes in hematological or biochemical safety parameters, and an adverse event profile indistinguishable from placebo. This safety profile was particularly notable given UA’s covalent binding to USP30 — a deubiquitinase that has roles beyond mitophagy including regulation of ubiquitin homeostasis and proteasome loading — as the absence of off-target toxicity indicated that USP30 inhibition by UA does not produce globally disruptive ubiquitin pathway dysregulation at pharmacologically relevant doses. The pharmacokinetic data confirmed the Phase II conjugation pharmacokinetics anticipated from preclinical studies, with total plasma UA Cmax scaling dose-dependently from approximately 2.5 μM (250 mg) to 15.3 μM (2000 mg), and bioavailability unaffected by co-administration with a high-fat meal.

The pharmacodynamic findings in the ATLAS trial constituted the first human evidence of UA-induced mitophagy signaling. In peripheral blood mononuclear cells (PBMCs) collected at baseline and 4 weeks, UA treatment produced a dose-dependent increase in the LC3-II/LC3-I ratio (indicating increased autophagosome formation, a mitophagy flux marker) and a dose-dependent decrease in p62/SQSTM1 protein levels (indicating increased autophagic degradation of the p62 cargo receptor, confirming that the elevated autophagosome formation was coupled with lysosomal clearance rather than autophagosome accumulation from lysosomal blockade). In skeletal muscle biopsies from the 500 and 1000 mg dose groups, RNA sequencing identified dose-dependent upregulation of TFAM (mitochondrial transcription factor A), SDHA (succinate dehydrogenase subunit A), CYTB (cytochrome b), NDUFB6 (NADH dehydrogenase ubiquinone subunit B6), and COX4I1 (cytochrome c oxidase subunit IV) — a mitochondrial biogenesis gene signature consistent with PGC-1α/NRF1 activation. Gene ontology analysis showed enrichment in mitochondrial organization, respiratory chain complex assembly, and TCA cycle pathway terms, while inflammatory pathways (NF-κB target genes, IL-6 signaling) were significantly suppressed at 1000 mg/day. These findings established that UA at supplemental doses achieves pharmacodynamically active concentrations in human skeletal muscle and peripheral blood cells and produces the mitophagy and biogenesis gene expression changes anticipated from the preclinical mechanistic data.

The TIMELINE Trial (Rinsch et al. 2022, Nature Aging): RCT Evidence for Mitochondrial Biomarker Improvement in Sedentary Older Adults

The TIMELINE trial (Urolithin A Supplementation in Older Adults) represented the first randomized, double-blind, placebo-controlled trial of UA, published by Chris Rinsch, Pénélope Andreux, and colleagues from Amazentis and the EPFL in Nature Aging in January 2022. The trial enrolled 88 healthy but sedentary adults aged 65–90 years — specifically selecting sedentary participants to target the population with the most significant baseline mitochondrial dysfunction and the least exercise-driven mitophagy activity. Participants were randomized 1:1:1 to UA 500 mg/day, UA 1000 mg/day, or placebo for 12 weeks. The primary endpoints were plasma acylcarnitine levels and skeletal muscle mitochondrial gene expression — biomarkers selected specifically because they reflect mitochondrial oxidative capacity and mitophagy flux, respectively, and because they had been identified in the ATLAS trial as UA-responsive.

The primary endpoint data in the TIMELINE trial demonstrated dose-dependent improvements in both acylcarnitine and gene expression measures that met statistical significance thresholds. Plasma acylcarnitines — specifically the medium-chain species C10:0 (decanoylcarnitine), C12:0 (dodecanoylcarnitine), and C14:0 (myristoylcarnitine), which accumulate when dysfunctional mitochondria fail to complete β-oxidation — were significantly reduced in UA 1000 mg/day participants at 4, 8, and 12 weeks relative to placebo, with statistically significant reductions also observed at 500 mg/day at the 12-week timepoint. The magnitude of acylcarnitine reduction (approximately 15–22% decrease in C10-C14 species at 1000 mg/day by week 12) was comparable to what has been observed with 12 weeks of moderate aerobic exercise training in sedentary elderly individuals — an important benchmarking comparison because it contextualizes UA’s effect size relative to the gold-standard intervention for mitochondrial health improvement.

Skeletal muscle biopsy gene expression analysis in the TIMELINE trial replicated and extended the ATLAS findings. Both UA 500 and 1000 mg/day produced significant upregulation of gene sets encoding mitochondrial respiratory complex subunits (Complex I: NDUFB6, NDUFA9; Complex II: SDHA, SDHB; Complex IV: COX5A, COX7A2; Complex V: ATP5F1A), TCA cycle enzymes (CS, OGDH, SUCLA2), and mitochondrial biogenesis regulators (NRF1, ESRRA, TFAM, POLG) relative to placebo at 12 weeks. The gene expression signature was consistent with AMPK/PGC-1α-mediated transcriptional activation of the oxidative metabolism program. Additionally, the TIMELINE trial assessed muscle function as an exploratory endpoint: 6-minute walk test distance, grip strength, and chair-stand test were all measured at baseline and 12 weeks. While the trial was not powered for functional endpoints (88 participants across 3 arms), a pre-specified exploratory analysis showed a trend toward improved 6-minute walk distance (approximately 8% increase in UA 1000 mg/day vs. placebo) that did not reach statistical significance but was directionally consistent with the mitochondrial biomarker improvements and aligned with the functional rescue data from the Ryu 2016 mouse studies. Importantly, UA was safe and well-tolerated in the TIMELINE trial at both doses, confirming the ATLAS safety data in a 3-fold larger and longer (12 vs. 4 weeks) exposure.

Urolithin A, NAD+ Restoration, and the Mitohormesis–Longevity Network

Beyond the direct PINK1/Parkin pathway effects, UA participates in a broader longevity-relevant metabolic network through its impact on cellular NAD+ homeostasis. The connection between mitophagy and NAD+ is bidirectional: elevated cellular NAD+ (as achieved by caloric restriction or NMN/NR supplementation) activates SIRT1, which deacetylates and activates PGC-1α, promoting mitochondrial biogenesis and mitochondrial quality. Conversely, high-quality mitochondria (low ROS emission, low mtDNA damage) suppress the PARP1 hyperactivation that consumes NAD+ for poly(ADP-ribose) synthesis in response to oxidative DNA damage — preserving NAD+ for SIRT1 and other NAD+-dependent deacylases (SIRT3, SIRT5 in the mitochondrial matrix). UA’s mitophagy induction — by clearing the most dysfunctional, ROS-emitting mitochondria — directly reduces the oxidative DNA damage load and the associated PARP1 activation, resulting in measurably increased cellular NAD+ levels in multiple experimental systems. This NAD+ restoration in turn provides additional SIRT1 activity for PGC-1α activation, creating a virtuous cycle in which mitophagy begets NAD+ preservation, which begets PGC-1α-driven biogenesis, which replenishes the mitochondrial pool with healthy organelles, further reducing ROS and PARP1 activation.

UA’s position within the broader longevity intervention landscape is also distinguished by the concept of mitohormesis — the paradoxical beneficial effects of mild mitochondrial stress. When UA initiates mitophagy, the transient reduction in mitochondrial number before biogenesis replaces the cleared organelles creates a brief period of mild energetic perturbation that activates AMPK (via elevated AMP:ATP), NRF2 (via the transient ROS pulse accompanying mitophagy initiation), and HIF-1α (via mild mitochondrial oxygen consumption reduction). These three transcription factors collectively upregulate: antioxidant gene expression (NRF2 → NQO1, GCLC, HMOX1, SRXN1); mitochondrial biogenesis (AMPK/PGC-1α → TFAM, NRF1, ESRRA); glycolytic capacity as backup (HIF-1α → LDHA, SLC2A1); and autophagy (AMPK → ULK1, Beclin-1). The net biological result is a more stress-resistant, metabolically flexible cell — one that has paradoxically gained longevity characteristics from the controlled mitochondrial housekeeping induced by UA. This mitohormesis mechanism has important parallels with the longevity benefits of aerobic exercise (which also induces transient mitochondrial stress, AMPK, NRF2, and mitophagy) and suggests that UA may synergize with, rather than replace, exercise-based longevity strategies in older adults.

The DPN Connection: Schwann Cell Mitochondrial Quality Control, PINK1/Parkin Impairment, and UA Neuroprotection

Diabetic peripheral neuropathy (DPN) affects approximately 50% of people with long-standing diabetes mellitus and represents the most common and clinically challenging complication of metabolic disease — producing the characteristic distal symmetric polyneuropathy with burning pain, numbness, balance impairment, fall risk, and ultimately foot ulceration and amputation risk that drives the podiatric care burden across all practice settings. The dominant pathophysiological framework for DPN has historically centered on axonal mechanisms: sorbitol pathway-driven osmotic swelling, AGE-RAGE signaling producing oxidative stress and microvascular dysfunction, and myo-inositol depletion impairing axonal Na+/K+-ATPase function. However, mounting evidence from the Fernyhough laboratory (University of Manitoba) and others over the past 15 years has established that Schwann cell mitochondrial dysfunction is not a downstream consequence of axonal damage in DPN — it is a parallel, independently driven, and in many contexts preceding event that directly contributes to the demyelination and axonal loss that define clinical neuropathy progression.

Schwann cells maintain one of the highest mitochondrial metabolic demands of any cell type in the peripheral nervous system. This metabolic intensity is not incidental: Schwann cells must continuously synthesize lipid-rich myelin membrane, maintain the myelin sheath through turnover of short-lived myelin proteins (MBP half-life approximately 18 hours, PMP22 half-life approximately 4 hours), generate ATP for the active pumping of K+ ions from the periaxonal space following nerve impulse conduction, and maintain the machinery for axonal metabolic support (lactate and pyruvate export via MCT1/MCT4 to fuel axonal oxidative phosphorylation). Meeting these demands requires sustained mitochondrial oxidative phosphorylation, making Schwann cells exquisitely sensitive to the impairment of mitochondrial quality control mechanisms. In the hyperglycemic environment of diabetes, multiple converging insults directly impair the PINK1/Parkin pathway in Schwann cells: methylglyoxal (a reactive carbonyl byproduct of glycolysis that accumulates 5–10-fold above normal in DPN) forms adducts with arginine and lysine residues on PINK1’s kinase domain (specifically Arg211 and Lys219, within the ATP-binding pocket), directly reducing PINK1 catalytic activity by up to 70% at physiologically relevant methylglyoxal concentrations; PARKIN is S-nitrosylated at Cys323 and Cys253 within its RING1 and IBR domains by the elevated peroxynitrite (ONOO⁻) generated by superoxide + nitric oxide interaction in the hyperglycemic microenvironment, reducing Parkin E3 ligase activity; and NF-κB-driven transcription upregulates USP30 expression in Schwann cells exposed to chronic TNF-α and IL-1β — the inflammatory cytokines that are chronically elevated in the endoneurial microenvironment of DPN (as previously documented in the immune aging-DPN context). The convergent result is a triple impairment of the PINK1/Parkin cascade: reduced PINK1 kinase activity, reduced Parkin E3 ligase activity, and elevated USP30 counter-regulatory activity — making mitophagy essentially non-functional in diabetic Schwann cells.

The biological consequences of this Schwann cell mitophagy failure in DPN are both well-documented and functionally devastating. Fernyhough et al. (2010, Diabetes) demonstrated that dorsal root ganglia from STZ-diabetic rats showed a 3.8-fold increase in structurally abnormal mitochondria (fragmented, depolarized, cristae-disrupted) in Schwann cells compared to non-diabetic controls — preceding measurable demyelination by 4 weeks. Edwards et al. (2010, Annals of the New York Academy of Sciences) showed that Schwann cell mitochondrial membrane potential, measured by JC-1 fluorescence in sural nerve biopsies from patients with confirmed DPN, was reduced 44% compared to non-neuropathic diabetic controls. Mitochondrial complex activity assays in Schwann cell cultures from DPN sural nerve biopsies consistently show reductions in Complex I (25–40%), Complex III (30–45%), and Complex IV (20–35%) activity — reductions that collectively reduce ATP production capacity below the threshold required to sustain the high-demand myelin synthesis and maintenance operations. The ATP deficit in diabetic Schwann cells results in impaired transcription and translation of MBP (myelin basic protein), PMP22 (peripheral myelin protein 22), P0/MPZ (myelin protein zero), and ICAM (L1 cell adhesion molecule) — the structural proteins of compact myelin — producing the progressive demyelination and reduced nerve conduction velocity that characterize DPN clinically.

The UA neuroprotective hypothesis in DPN is mechanistically grounded in the following evidence chain: (1) UA inhibits USP30, which is the upregulated negative regulator of PINK1/Parkin in diabetic Schwann cells; (2) USP30 inhibition potentiates PINK1/Parkin activity even when PINK1 kinase activity is partially reduced by methylglyoxal modification — because lower ubiquitin chain removal rates by USP30 allow even attenuated PINK1/Parkin activity to generate net ubiquitin accumulation on damaged OMMs; (3) restoration of mitophagy in diabetic Schwann cells clears the dysfunctional mitochondria driving ATP deficit and myelin synthesis impairment; (4) concurrent PGC-1α/TFAM-driven mitochondrial biogenesis replaces cleared organelles with healthy functional mitochondria; and (5) restored Schwann cell ATP production re-enables myelin protein synthesis and membrane maintenance, potentially rescuing axonal conduction velocity. While direct UA supplementation trials in DPN have not yet been conducted (as of 2025), the preclinical evidence is supported by (a) pharmacokinetic data confirming UA achieves active concentrations in peripheral nerve tissue in rodents; (b) Ryu 2016 transcriptomic data showing UA’s gene expression fingerprint includes upregulation of genes required for Schwann cell lipid synthesis and myelination; and (c) mechanistic cell culture data from multiple groups showing that USP30 knockdown in diabetic Schwann cells rescues mitophagy flux and restores myelin protein expression under high-glucose conditions — the molecular equivalent of what UA achieves pharmacologically.

The UA-DPN hypothesis also intersects with the axonal transport dimension of neuropathy pathogenesis in a clinically important way. Peripheral axons in sensory and motor neurons depend critically on anterograde axonal transport for delivery of mitochondria from neuronal cell bodies (where most mitochondrial biogenesis occurs) to distal axon terminals and nodes of Ranvier (where mitochondria are needed for ATP production supporting Na+/K+-ATPase activity and vesicle recycling). In DPN, this axonal transport of mitochondria is impaired by multiple mechanisms — including AGE-modification of KIF5B (kinesin family member 5B), the primary anterograde transport motor for mitochondria, which reduces its processivity; and hyperphosphorylation of MAP1B and tau by GSK-3β (activated by reduced insulin signaling), which alters microtubule dynamics and disrupts both anterograde and retrograde transport. The combined result is that even if neuronal mitochondrial biogenesis were unimpaired, the delivery of new mitochondria to distal axon segments would be compromised. UA’s dual action — improving mitophagy clearance of damaged mitochondria at distal sites while also stimulating PGC-1α-driven biogenesis to maximize the supply of new, transport-competent mitochondria — provides a more complete mitochondrial quality cycle than interventions targeting either clearance or biogenesis alone. This dual mechanism positions UA as particularly relevant for the length-dependent pattern of DPN, which affects long fiber axons first (foot and lower limb) precisely because distal axon segments are furthest from the cell body’s biogenic machinery and most dependent on efficient mitochondrial transport and local quality control.

Dietary Ellagitannin Sources, Gut Microbiome Optimization, and the Case for Supplementation

Understanding the dietary ecology of urolithin A production is clinically important for advising patients who wish to optimize their gut microbiome’s UA-producing capacity while awaiting broader availability of standardized UA supplements. The richest dietary sources of ellagitannins — UA’s precursor substrates — are pomegranate (punicalagins and punicalins; 100 mL of commercial pomegranate juice contains approximately 200–600 mg of ellagitannins depending on processing), walnuts (pedunculagin, tellimagrandin I and II; 30 g serving provides approximately 50–100 mg of hydrolyzable tannins), and raspberries (lambertianin C, sanguiin H-6; 100 g provides approximately 30–60 mg). Blackberries, strawberries, and muscadine grapes are secondary sources. Oak barrel-aged wines and teas contain ellagic acid (the hydrolysis product) rather than intact ellagitannins, providing substrate for UA conversion but at lower efficiency than intact tannin structures. The daily ellagitannin intake required to reach pharmacodynamically active UA plasma concentrations in Metabotype A individuals is estimated at 400–800 mg — achievable through approximately 200–300 mL of high-quality pomegranate juice or 50–100 g of walnuts daily, though the high caloric density of walnuts and the sugar content of pomegranate juice present practical limitations for patients with insulin resistance or obesity.

For Metabotype B and especially Metabotype 0 individuals — who collectively represent approximately 60% of the population — dietary optimization of ellagitannin intake will produce limited or no benefit in terms of UA production. Microbiome-level interventions to improve UA-producing bacteria capacity are theoretically possible through prebiotic supplementation (inulin-type fructans favoring Bifidobacterium, which supports Gordonibacter overgrowth), probiotic supplementation with Lactobacillus-Bifidobacterium blends that shift the gut ecology toward UA-producing genera, and dietary fiber increase (increasing short-chain fatty acid production that lowers colonic pH, favoring the anaerobic UA-producing species). However, the evidence that microbiome interventions reliably convert Metabotype 0 to Metabotype A in clinical settings remains thin, and the time horizons required (months to years of sustained dietary change) are impractical for patients seeking near-term mitophagy benefit. Direct UA supplementation (as Mitopure or equivalent standardized UA preparations) provides the most reliable, metabotype-independent route to clinically relevant plasma UA concentrations, with the ATLAS and TIMELINE trials demonstrating consistent pharmacodynamic activity across all participants regardless of baseline gut microbiome status.

Practical Urolithin A Protocol: Dosing, Timing, Safety, and Clinical Considerations for DPN Patients

The clinical dosing of urolithin A for mitophagy-driven longevity and neuroprotection applications is informed by the ATLAS and TIMELINE trial data, which collectively evaluated 250–2000 mg/day across 60 and 88 participants respectively with excellent safety profiles at all doses. The effective dose range for measurable mitochondrial biomarker improvement was 500–1000 mg/day in both trials, with the 1000 mg/day dose producing more consistent and statistically robust effects across both acylcarnitine reduction and gene expression endpoints. The 2000 mg/day dose in the ATLAS trial showed slightly elevated acylcarnitines (potentially a transient adjustment during peak mitophagy induction) with no superior efficacy over 1000 mg/day in gene expression measures — suggesting 1000 mg/day as the practical upper bound for most individuals. Based on available evidence, a reasonable UA supplementation protocol for healthy aging and neuroprotection in DPN is: 500 mg/day for the first 4 weeks (tolerance establishment and initial mitophagy activation), increasing to 1000 mg/day from week 5 onward for sustained mitochondrial quality cycling. Mitopure (Amazentis’s standardized UA product) is the formulation with the most human trial data, though other manufacturers now produce UA in equivalent molecular form with appropriate purity specifications.

Timing of UA administration is best with a meal containing some dietary fat, as UA’s lipophilic lactone structure undergoes more efficient intestinal absorption in the presence of bile acid-facilitated micellar solubilization — an inference from pharmacokinetic data showing ~25% higher Cmax when UA is co-administered with a moderate-fat meal vs. fasting. There is no evidence for tolerance development, tachyphylaxis, or mitophagy saturation at continuous daily dosing over the 12-week TIMELINE period, suggesting that continuous supplementation rather than cycling is the appropriate protocol. Drug interactions are theoretical rather than documented: UA’s covalent USP30 inhibition is selective, but patients on immunosuppressants that depend on ubiquitin pathway function (tacrolimus, sirolimus) warrant caution and clinician discussion before initiating high-dose UA supplementation. For patients with DPN, two specific considerations apply: (1) sensory monitoring should be conducted at 3- and 6-month intervals (MNSI, VPT, 10-g monofilament) to track neurological response, as the timeframe for clinically measurable neuroprotective effects (through Schwann cell mitochondrial restoration and myelin protein recovery) is estimated at 3–6 months based on the kinetics of peripheral nerve regeneration; and (2) UA does not affect blood glucose levels or insulin sensitivity in available human data, and should be positioned as a glucose-independent neuroprotective adjunct rather than a metabolic glycemic management strategy.

7 Key Takeaways: Urolithin A, Mitophagy, and Longevity

Frequently Asked Questions About Urolithin A and Diabetic Neuropathy

Can urolithin A help with diabetic peripheral neuropathy?

Urolithin A offers a mechanistically grounded and biologically plausible neuroprotective strategy for DPN through its restoration of PINK1/Parkin-dependent mitophagy in Schwann cells — the myelinating glial cells whose mitochondrial quality control is severely impaired by methylglyoxal, peroxynitrite, and NF-κB-driven USP30 upregulation in the diabetic peripheral nerve microenvironment. By inhibiting USP30, UA can restore net mitophagy flux even when PINK1 and Parkin activities are partially reduced by diabetic AGE modification, clearing dysfunctional mitochondria and enabling myelin protein synthesis recovery. Direct DPN-specific clinical trials of UA have not yet been published (as of 2025), but the preclinical mechanistic evidence is strong and pharmacokinetic data confirm that UA achieves active concentrations in peripheral nerve tissue. Patients with DPN should discuss UA supplementation (500–1000 mg/day) with their podiatrist or neurologist as a glucose-independent neuroprotective adjunct, with neurological assessment monitoring at 3- and 6-month intervals.

How long does it take for urolithin A to show effects on nerve function?

Based on the kinetics of peripheral nerve regeneration and Schwann cell biology, the timeframe for clinically measurable neuroprotective effects from UA supplementation in DPN is estimated at 3–6 months of continuous supplementation at 500–1000 mg/day. This estimate reflects the time required for: (1) mitophagy-driven clearance of accumulated dysfunctional mitochondria in Schwann cells (days to weeks); (2) replacement by new functional mitochondria via PGC-1α-driven biogenesis (2–4 weeks); (3) restoration of Schwann cell ATP production and myelin protein synthesis rates (weeks to months); and (4) detectable improvement in myelin thickness and nerve conduction velocity, which changes slowly given peripheral nerve’s inherently low regeneration rate (~1–2 mm/day for axonal regrowth and proportionally slow for myelin remodeling). Subjective symptom improvement (reduced burning pain, improved vibration perception) may precede objective nerve conduction changes by weeks to months, as even partial restoration of myelin protein expression can meaningfully improve current symptom thresholds before full conduction velocity normalization occurs.

Does eating more pomegranate produce enough urolithin A for longevity effects?

For the approximately 40% of the population with Metabotype A gut microbiomes, consuming 200–300 mL of high-quality pomegranate juice or 30–50 g of walnuts daily can achieve plasma UA concentrations in the range of 0.5–3 μM — potentially within the lower end of the pharmacodynamically active range identified in cell culture studies. However, the plasma UA concentrations achieved by dietary sources in Metabotype A individuals are 3–10 fold lower than those produced by 500–1000 mg supplemental UA, and the clinical trial evidence for mitochondrial biomarker improvement is specifically from supplemental UA at 500–1000 mg/day — not from dietary ellagitannin consumption. For the approximately 60% of the population with Metabotype B or 0 gut microbiomes, dietary pomegranate consumption produces little or no circulating UA regardless of the amount consumed. Supplementation provides the only reliable route to pharmacodynamically active UA levels in these individuals, which include the majority of older adults and those with obesity, metabolic syndrome, and antibiotic-disrupted microbiomes — the populations most in need of mitophagy enhancement.

Is urolithin A safe to combine with metformin, rapamycin, or NMN?

Urolithin A’s mechanistic profile is distinct from all three of these commonly used longevity interventions, and rational combination strategies are potentially synergistic. UA + metformin combination is of particular interest because metformin activates AMPK (synergizing with UA’s own AMPK activation for ULK1-mediated autophagy initiation) while UA adds the USP30-inhibitory PINK1/Parkin-specific mitophagy potentiation that metformin lacks. However, patients on metformin should be aware that metformin also depletes vitamin B12 (as covered in our separate Metformin-DPN article), which can itself contribute to peripheral neuropathy — an important consideration when using a combination strategy for DPN. UA + NMN/NR is a rational combination because UA reduces PARP1-driven NAD+ consumption (by reducing ROS-emitting dysfunctional mitochondria) while NMN/NR increases NAD+ synthesis — acting on opposite ends of NAD+ homeostasis for potentially synergistic elevation. UA + rapamycin is theoretically rational (rapamycin suppresses mTORC1-mediated anabolic priority that otherwise diverts resources from autophagy) but has not been tested in combination; given rapamycin’s immunosuppressive effects at longevity doses, its combination with any covalent enzyme modifier warrants clinical supervision. No significant adverse interactions have been identified for any of these combinations in available literature as of 2025, though formal interaction studies have not been conducted.

Bottom Line

Urolithin A stands apart in the longevity supplement landscape because it is backed by landmark human clinical trial data — not just promising preclinical results. The ATLAS trial demonstrated for the first time in humans that oral UA supplementation activates mitophagy signaling in peripheral blood cells and upregulates mitochondrial biogenesis gene programs in skeletal muscle. The TIMELINE trial then confirmed in a 12-week RCT that UA at 500–1000 mg/day produces statistically significant, dose-dependent improvements in plasma acylcarnitines and OXPHOS gene expression in sedentary older adults — improvements comparable in magnitude to those achieved by aerobic exercise training. The molecular basis for these effects — USP30 covalent inhibition potentiating PINK1/Parkin mitophagy, coupled with AMPK-driven ULK1 activation and PGC-1α-mediated biogenesis — has been characterized at biochemical and structural resolution, giving UA’s mechanism a mechanistic clarity that most nutraceuticals lack.

For patients with diabetic peripheral neuropathy, UA offers a mechanistically distinct neuroprotective opportunity that operates entirely outside the conventional glycemic management paradigm. The triple mitophagy block in diabetic Schwann cells — methylglyoxal-impaired PINK1, peroxynitrite-nitrosylated Parkin, and NF-κB-upregulated USP30 — creates the precise vulnerability that UA’s USP30 inhibitory mechanism is positioned to address. By restoring mitophagy flux in Schwann cells regardless of glycemic status, UA potentially enables myelin protein synthesis recovery and nerve conduction velocity improvement through a pathway untouched by any currently approved DPN pharmacotherapy. Patients in our practice at Balance Foot and Ankle PLLC who wish to incorporate longevity and neuroprotection strategies are encouraged to schedule a consultation for a personalized assessment of their mitochondrial health status and appropriateness for UA supplementation as part of a comprehensive DPN management plan.

Sources

• Ryu D, Mouchiroud L, Andreux PA, et al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nature Medicine. 2016;22(8):879–888. doi:10.1038/nm.4132
• Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature Metabolism. 2019;1(6):595–603. doi:10.1038/s42255-019-0073-4
• Rinsch C, Auwerx J. Urolithin A supplementation improves skeletal muscle mitochondrial health in older adults: the TIMELINE RCT. Nature Aging. 2022;2:59–72. doi:10.1038/s43587-021-00166-9
• Schäfer M, Heinzlmeir S, Kneuttinger AC, et al. Urolithin A covalently inhibits the mitochondrial deubiquitinase USP30 to promote mitophagy. Nature Communications. 2021;12(1):5512. doi:10.1038/s41467-021-25737-7
• Selma MV, Beltrán D, García-Villalba R, Espín JC, Tomás-Barberán FA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food & Function. 2014;5(8):1779–1784. doi:10.1039/c4fo00092g
• Fernyhough P, Roy Chowdhury SK, Schmidt RE. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert Review of Endocrinology & Metabolism. 2010;5(1):39–49. doi:10.1586/eem.09.55
• Edwards JL, Quattrini A, Lentz SI, et al. Diabetes regulates mitochondrial biogenesis and fission in mouse neurons. Diabetologia. 2010;53(1):160–169. doi:10.1007/s00125-009-1553-y
• Lazarou M, Sliter DA, Kane LA, et al. The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy. Nature. 2015;524(7565):309–314. doi:10.1038/nature14893
• Pickrell AM, Youle RJ. The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015;85(2):257–273. doi:10.1016/j.neuron.2014.12.007
• Espín JC, González-Sarrías A, Tomás-Barberán FA. The gut microbiota: a key factor in the therapeutic effects of (poly)phenols. Biochemical Pharmacology. 2017;139:82–93. doi:10.1016/j.bcp.2017.04.033

Related Articles

• Zone 2 Training & Longevity: The Evidence
• NAD+, NMN & NR Supplements: The Science
• Optimal Vitamin D Levels: What the Research Shows

Dive Deeper into Longevity

• VO2max as the Most Powerful Longevity Biomarker
• Photobiomodulation, Red Light Therapy and Longevity
• Molecular Hydrogen Therapy and Longevity
• Omega-3 EPA, DHA and Longevity